Expression and localization of fibroblast growth factors and fibroblast growth factor receptors in the developing rat kidney  by Cancilla, Belinda et al.
Kidney International, Vol. 56 (1999), pp. 2025–2039
GENETIC DISORDERS – DEVELOPMENT
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Expression and localization of fibroblast growth factors and The development of the permanent kidney, or meta-
fibroblast growth factor receptors in the developing rat kidney. nephros, is a complex process involving reciprocal induc-
Background. The permanent kidney, or metanephros, de- tive events. In the first instance, the ureteric bud is inducedvelops through a complex series of reciprocal inductive events
to grow into the metanephric blastema. Ureteric epithe-and involves branching morphogenesis, tubulogenesis, angio-
lium induces mesenchymal condensation, whereas meta-genesis, and tissue remodeling. Fibroblast growth factors
(FGFs) are a family of growth and differentiation factors that nephric mesenchyme induces ureteric branching. The
have been implicated in metanephric development. FGFs exert mesenchymal condensate converts to epithelium and dif-
their actions through tyrosine kinase receptors, FGFRs, which ferentiates through a comma-shaped body, S-shapedare encoded by four FGFR genes (FGFR1 through FGFR4).
body, and capillary loop stage glomerulus to a maturingMethods. Reverse transcriptase-polymerase chain reaction
was used to detect the expression of FGFs and FGFRs in rat glomerulus [1]. The developing loop of Henle proceeds
metanephroi from embryonic day (E) 14 to E21. Nonradioac- through three stages: (a) the primitive loop of Henle,
tive in situ hybridization was used to localize FGF1 mRNA in which consists of thick undifferentiated epithelium; (b)
E20 rat metanephroi, and immunohistochemistry was used to
the immature loop of Henle, which has thin immaturelocalize FGFRs in E15 and E20 rat metanephroi.
epithelium in the descending portion and distal tubuleResults. We detected the expression of mRNAs for FGF1
through FGF5, FGF7 through FGF10, and FGFR1 through epithelium in the ascending portion; and (c) the maturing
FGFR4 (IIIb and IIIc splice variants) in rat metanephroi from loop of Henle, which consists of a thin limb and a distal
E14 to E21. By in situ hybridization, FGF1 mRNA was detected straight tubule [2].in the nephrogenic zone, ureteric epithelium, and developing
Many growth factors have been shown to play keynephron elements. FGFR proteins were localized in a distinct
roles in metanephric development [3–6], including mem-pattern that altered with maturation. FGFR1 was widely dis-
tributed in developing metanephric epithelia and mesenchyme, bers of the fibroblast growth factor (FGF) family. The
but not in developing interstitium. FGFR2 was also widely FGF family has at least 19 members [7], only some of
distributed in nephron epithelia, particularly in proximal con-
which have been examined in the kidney. FGF1 and FGF2voluted tubules, but was not detected in metanephric mesen-
are present in both adult and embryonic kidneys, andchyme, mesenchymal condensates, or developing interstitium.
FGFR3 was localized to mesenchymal condensates, nephron crude kidney extracts have mitogenic and angiogenic ac-
elements, and medullary interstitium but not proximal convo- tivity caused by FGF2 [8]. Exogenous FGF2 can stimulate
luted tubules. FGFR4 was localized mostly to maturing neph- condensation of isolated rat metanephric mesenchymeron structures and was not detected in nephrogenic mesen-
in vitro [9], a critical early event in nephron development.chyme, mesenchymal condensates, or developing interstitium.
Previous studies have examined the expression ofConclusions. These results indicate that FGFs and FGFRs
are expressed in the developing rat metanephros from at least FGF1 [10], FGF2 [11], FGF7 [12], and FGF8 [13, 14] in
E14 and that they likely play important roles in metanephric human or rodent metanephroi. However, in these stud-
development and maturation.
ies, only one developmental time point was examined.
FGF2 mRNA has been localized to tubular epithelia,
1 Current address: Department of Anatomy, Monash University, mesangial cells, and surrounding mesenchyme in human
Clayton, Victoria, Australia. metanephroi at mid-gestation using radioactive in situ
hybridization [11]. We have previously shown using im-Key words: growth factor, metanephros, kidney maturation, develop-
ment, nephrogenic zone. munohistochemistry that FGF1 and FGF2 are present
from at least embryonic day 14 (E14) in rat kidneys [15].Received for publication December 1, 1998
We found that FGF1 and FGF2 were colocalized in meta-and in revised form April 13, 1999
Accepted for publication July 19, 1999 nephroi throughout gestation and in ureteric epithelium,
glomeruli, and developing nephron tubules. Although 1999 by the International Society of Nephrology
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several studies have examined the localization of FGF1 Within metanephroi, FGFR4 mRNA was found in col-
lecting tubules at E14.5.protein in kidneys, these reports are conflicting. There-
Previous studies have not determined when FGFR2,fore, we have used nonradioactive in situ hybridization
FGFR3, or FGFR4 are first expressed in rat metanephroito determine the localization of FGF1 mRNA in rat
and have not determined which IIIb or IIIc FGFR vari-metanephroi.
ants are present. Although several in situ hybridizationThe FGF family of ligands signals through specific trans-
studies have reported localization of FGFR mRNAs inmembrane protein tyrosine kinase receptors (FGFRs).
metanephroi, localization of FGFR protein has onlyEfficient receptor dimerization and activation also require
been studied for FGFR1 in human tissues.endogenous heparan sulfate proteoglycans (HSPGs),
In this study, we have shown using RT-PCR thatwhich avidly bind FGFs and facilitate their binding to
mRNAs for FGF1 through FGF5, FGF7 through FGF10FGFRs [16, 17]. During metanephric development, sul-
are present in rat metanephroi from E14 to E21. Tofated proteoglycans are initially produced at the ureteric
complement this work and to add to our previous local-bud tips. These then surround developing nephron ele-
ization studies of FGF2 [15], we have used nonradioac-ments and are found in basement membranes through-
tive in situ hybridization histochemistry to localize theout the metanephros [18]. Four genes encode the FGFRs,
expression of FGF1 in E20 rat metanephroi. With RT-which are characterized by three immunoglobulin-like
PCR, we have shown that mRNAs for FGFR1 through(Ig) loops in the extracellular domain, a transmembrane
FGFR4 are present in rat metanephroi from E14 to E21,region and a split intracellular tyrosine kinase domain
and in addition, we have also determined which IIIb or[17]. Alternative mRNA splicing of the Ig-III domain of
IIIc FGFR variants were expressed and the onset ofFGFR1 through FGFR3 gives rise to IIIb or IIIc FGFR
their expression. Finally, avidin-biotin–enhanced indi-variants. FGFR4 does not have alternative splicing of
rect immunohistochemistry was used to localize FGFR1the Ig-III domain [17]. Studies on cell lines expressing
through FGFR4 proteins in E15 and E20 rat meta-a single type of FGFR variant have revealed that apart
nephroi. Together, these data provide a basis for futurefrom FGF1, which activates all FGFRs, each FGF acti-
functional studies into the roles of FGFs in developingvates a particular subset of receptor variants [19, 20].
metanephroi. In light of the preference of particularConsequently, the expression of a particular FGFR vari-
FGFs for signaling through specific FGFR variants, theant by a tissue/cell will determine to which FGF ligand
localization of FGFRs to specific nephron compartmentsthat tissue/cell can respond.
suggests that these regions may be targets for particularSeveral studies have examined the expression of
FGFs. They indicate that other members of the FGFFGFRs in metanephroi. Northern blot analysis of 17- to
family, in addition to the well-studied FGF1 and FGF2,
18-week-old human fetal tissues demonstrated that
may play important roles in kidney development.
FGFR1, FGFR2, FGFR3, and FGFR4 mRNAs are pres-
ent in developing human kidneys [21]. Splice variants
METHODSin loop I and loop II of FGFR1 are expressed in rat
metanephroi and were detected by reverse transcriptase- Animals
polymerase chain reaction (RT-PCR) at E14, E17, and Pregnant time-mated female Sprague-Dawley rats
E20 [22]. FGFR1, FGFR3, and FGFR4 have also been were anesthetized with an intraperitoneal injection of
detected by RT-PCR in E21 rat kidneys [23]. pentobarbitone sodium (Nembutal; Boehringer Ingel-
Fibroblast growth factor receptor 1 mRNA has been heim, Artarmon, NSW, Australia) at 5 mg/100 g body
localized in rat [24] and mouse [25, 26] metanephroi in wt. A midline abdominal incision was made, and the
condensates and comma- and S-shaped bodies, and some uterus was located. Fetal rats were removed from the
localization was also detected in ureteric bud branches. uterus, detached from the placenta, and quickly decapi-
In human metanephroi, FGFR1 protein and mRNA tated. The mothers were euthanized, and a sample of
have been localized in renal tubules and early nephron skeletal muscle was removed for positive control RNA.
structures [11]. FGFR2 expression has been localized in Metanephroi were dissected from fetal rats at each day
collecting ducts and some nephron tubules of mouse of gestation from E14 to E21. E0 was defined as the time
embryos [25, 26]. (61 hr) at which the vaginal plug was found, and fetuses
In situ hybridization for FGFR3 IIIb and IIIc splice were dissected at or close to this time of day. All animal
variants detected mRNA for IIIb but not IIIc in urinary experiments were approved by the University of Mel-
tract epithelia of E14 and E20 mouse embryos, although bourne Animal Experimentation Ethics Committee and
the metanephros was not examined [27]. In situ hybrid- were in accordance with the Australian Code of Practice
ization studies on the expression pattern of FGFR4 in for the Care and Use of Animals for Scientific Purposes.
murine development have shown that it is expressed For isolation of mRNA for RT-PCR, metanephroi
were dissected from two sets of 24 fetal rats at each agein a number of tissues, including metanephroi [28, 29].
Cancilla et al: FGFs and FGFRs in developing kidney 2027
from E14 to E21 and were snap frozen in liquid nitrogen; and reverse (59-TAGTTCAGGTACTTTGTCAGG). For
skeletal muscle was collected from two females. Total amplification of FGF10, the primers used were forward
RNA was isolated using TRIzol reagent (Life Technolo- (59-ACATTGTGCCTCAGCCTTTC), internal (59-CAT
gies, Gaithersburg, MD, USA) following the manufac- GGTGTCACCGGAGGCTA), and reverse (59-TTCCA
turer’s instructions. mRNA was then isolated from the TTCAATGCCACATACAT). Oligonucleotide primers
metanephric RNA using the PolyATract mRNA Isola- used for amplification of FGFR1 through FGFR4 trans-
tion System (Promega, Madison, WI, USA) following membrane domains and FGFR1 through FGFR3 IIIb
the manufacturer’s instructions, and the resulting pellet and IIIc variants were identical to those used previously
was resuspended in 20 ml of RNase-free water. For im- for amplification from adult rat kidney [32].
munohistochemistry, metanephroi were fixed in Bouin’s After reverse transcription, 100 ng of forward primer
fixative for four hours and processed into paraffin, and and an Ampliwax gem (Perkin Elmer) were added to
3 mm serial sections were cut. Two mothers (with 12 fe- the cDNA, and the reaction tube was then heated and
tuses each) were used, and immunohistochemistry was cooled to allow a solid layer of wax to form over the
performed on two sets of serial sections from each set of samples. PCR components were then added to the
fetal rats. For in situ hybridization, metanephroi were cDNA, and the samples were heated to 958C for 120
fixed in 4% paraformaldehyde for two hours and were seconds to allow the wax to melt and cDNA and the
processed into paraffin, and 5 mm serial sections were cut. PCR components to mix. PCR conditions were denatur-
ation at 958C, annealing at 558C or 608C, and extensionReverse transcriptase-polymerase chain reaction
at 728C for 60 seconds each for 35 cycles. The controls
Reverse transcription and PCR were performed se- used for RT-PCR were to replace the RT with water
quentially in the same reaction tube using GeneAmp (non-RT control) and to replace mRNA with water (H2O
RNA PCR kit (Perkin Elmer, Foster City, CA, USA) control).
according to manufacturer’s instructions. Reverse tran- Reverse transcriptase-PCR products were electropho-
scription was performed with 2 ml isolated mRNA (or resed through 1.4% agarose gels and then alkaline capil-
total RNA) and 100 ng appropriate reverse primer to lary blotted onto Hybond N1 membrane (Amersham,
generate cDNA. Little Chalfont, Buckinghamshire, UK) as described in
Oligonucleotide primers used for amplification of FGF1 Sambrook, Fritsch, and Maniatis [33]. RT-PCR products
were p8 (reverse) and p9 (forward), with p10 as the inter- were detected by hybridization at 428C for 18 hours with
nal oligonucleotide [30]. For amplification of FGF2, p1 their respective internal oligonucleotides, which were ra-
(forward) and p2 (reverse) were used [31], with Ra1 [32] dioactively labeled by 59 end labeling using [g-32P]-adeno-
as the internal oligonucleotide used for Southern analysis.
sine 59-triphosphate ([g-32P]-ATP; Amersham) and T4
For amplification of FGF3, the primers used were forward
polynucleotide kinase (Boehringer Mannheim, Castle(59-GTGGCGTTTACGAGCACCTC), internal (59-GA
Hill, NSW, Australia). After stringent washes [to 0.5 3ACAAGAGAGGACGGCTG), and reverse (59-CACC
standard saline citrate (SSC), 0.1% sodium dodecyl sul-GACACGTACCAAGGTC). For amplification of FGF4,
fate (SDS) at 428C], membranes were exposed to autora-the primers used were forward (59-CAGTCTTCTGGAG
diographic film. The identity of most of the FGF and allCTCTCTC), internal (59-ACTGAGGGCCATGAACA
of the FGFR RT-PCR products detected by SouthernTAC), and reverse (59-GTTACCTTCATGGTAGGCG
analysis was confirmed by direct sequencing of PCRAC). For amplification of FGF5, primers used were for-
products on an automated ABI 310 Prism DNA se-ward (59-TCGGTTTCCATCTGCAGATC), internal
quencer (Applied Biosystems, Melbourne, Australia).(59-GCTGAACTTACAGTCATCTGTA), and reverse
(59-CTGGAACAGTGACGGTGAAG). For amplifica- Riboprobe production
tion of FGF6, the primers used were forward (59-CTCGT
Fibroblast growth factor 1 cDNA clones were derivedCTTCTTAGGCGTCCT), internal (59-CTACTGGACT
as previously described [30]. RT-PCR products for FGF1CCAGAGGCTG), and reverse (59-CCGTCCATATTTG
(approximately 160 bp) were blunt-end ligated into theCTCAGTG). For amplification of FGF7, the primers used
SmaI restriction site of pGEM-3Zf(1) vectors (Pro-were forward (59-CCGACTCCGCTCTACAGACC), in-
mega). Plasmids used for further experiments containedternal (59-TGTTCTGTCGCACCCAGTGG), and reverse
inserts oriented such that T7 RNA polymerase would(59-GTTGCAATCCTCATTGCATTC). For amplifica-
produce sense FGF1 cRNA and SP6 RNA polymerasetion of FGF8, the primers used were forward (59-ACAA
would produce antisense FGF1 cRNA. Plasmids wereGCGCATCAACGCCATG), internal (59-GGCAGGCG
linearized with EcoRI (for antisense riboprobes) or SalICTTCATGAAGTG), and reverse (59-GGCGGGTAGT
(for sense riboprobes) restriction endonucleases (Boeh-TGAGGAACTC). For amplification of FGF9, the prim-
ringer Mannheim). In vitro transcription of biotin-UTP–ers used were forward (59-AGGCAGCTGTACTGCA
GGAC), internal (59-TCTGGTGCCGTTTAGTCCTG), labeled cRNA probes with T7 and SP6 RNA polymer-
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ases was performed using the Riboprobe Gemini II primary antibodies were incubated on sections overnight
at 48C. Antibodies were detected by incubation withSystem (Promega) following the manufacturer’s instruc-
tions, with replacement of rUTP with 1 ml 20 mm biotin- biotinylated secondary antibody (Vector Laboratories)
for one hour, followed by incubation with avidin-biotin21-rUTP (Clontech, Palo Alto, CA, USA). The relative
size and concentration of the probes were assessed by horseradish peroxidase complex (Vectastain Elite ABC
kit; Vector Laboratories) for one hour and reacted toNorthern blot analysis (data not shown).
color with diaminobenzidine (Sigma Chemical).
In situ hybridization Affinity-purified rabbit polyclonal antibodies raised to
peptides mapping at the carboxy-terminus of FGFR1Nonradioactive in situ hybridization was performed
on sections of rat metanephroi from E20 fetuses as pre- (residues 808 to 822 of the human flg gene product),
FGFR2 (residues 805 to 821 of the human bek gene prod-viously described [34]. Briefly, paraffin sections were de-
waxed, rehydrated, and then treated with 0.1 m glycine, uct), FGFR3 (residues 792 to 806 of human FGFR3),
and FGFR4 (residues 789 to 802 of human FGFR4) were0.3% Triton X-100, digested with 50 mg/ml proteinase
K (Promega) at 378C for 30 minutes, postfixed in 4% purchased from Santa Cruz Biotechnology (Santa Cruz,
CA, USA) and used at 0.5 mg/ml. Each FGFR antibodyparaformaldehyde in phosphate-buffered saline, and
treated with 0.25% acetic anhydride. Sections were pre- was tested by immunoprecipitation and Western blotting
by Santa Cruz Biotechnology, and cross-reactivity withhybridized [in 50% formamide, 2 3 SSC, 0.3% bovine
serum albumin (BSA) and 1 mg/ml tRNA] at 428C for other FGFRs was not detected. These antibodies cannot
discriminate between the IIIb and IIIc functional vari-one hour. Fifty to 100 ng of biotin-UTP–labeled cRNA
probe were denatured at 758C for five minutes in 20 ml ants of each receptor and will, therefore, detect both
variants if present in the tissue. Control sections in thishybridization buffer [50% formamide, 2 3 SSC, 10%
polyethylene glycol (PEG), 0.3% BSA, 0.5% SDS, study were incubated with rabbit serum (Sigma Chemi-
cal) or with antibodies that had been preabsorbed with 20.25% polyvinylpyrrolidone, 0.02% Ficoll 400, 0.3% Tri-
ton X-100, 0.25 m Tris (pH 7), and 500 mg/ml tRNA] mg/ml immunizing peptides (Santa Cruz Biotechnology).
and cooled on ice, and then 20 U RNasin (Promega)
was added. Prehybridization solution was then drained
RESULTS
from the slide, and the probe solution was added. A
Reverse transcriptase-polymerase chain reactioncover slip was placed over the section, and the edges
were sealed with rubber cement. Sections were then hy- RT-PCR for FGF1 through FGF10. RT-PCR indi-
cated that mRNAs for FGF1 (307 bp RT-PCR product),bridized in a humid chamber at 428C overnight. The
cover slip was removed the next day by soaking the slide FGF2 (355 bp RT-PCR product), FGF3 (372 bp RT-
PCR product), FGF4 (261 bp RT-PCR product), FGF5in 2 3 SSC. Sections were then washed twice in 2 3 SSC
at 428C for 10 minutes each, followed by two washes in (414 bp RT-PCR product), FGF7 (384 bp RT-PCR prod-
uct), FGF8 (384 bp RT-PCR product), FGF9 (411 bpphosphate-buffered saline at 428C for 10 minutes each.
A blocking solution of 2% BSA, 0.3% Triton X-100 in RT-PCR product), and FGF10 (548 bp RT-PCR prod-
uct) were present in metanephroi from E14, E17, andTris-buffered saline (TBS; 0.9% NaCl in 0.1 m Tris, pH
7.4) was applied for 30 minutes. Sections were then incu- E21 rat embryos (Fig. 1). FGF6 (492 bp RT-PCR prod-
uct) was expressed in the positive control skeletal musclebated in an avidin-biotin horseradish peroxidase com-
plex (Vectastain Elite ABC kit; Vector Laboratories, but was not expressed in rat metanephroi. No RT-PCR
products were detected in the H2O or non-RT controlsBurlingame, CA, USA) for one hour, followed by two
washes with 0.3% Triton X-100 in TBS; they were then of any sample. The results are summarized in Table 1.
RT-PCR for FGFR1 through FGFR4 (tm) transmem-washed once with TBS. Sections were reacted to color
with 0.5 mg/ml diaminobenzidine (Sigma Chemical Co., brane domain. RT-PCR indicated that mRNAs for
FGFR1 (446 bp RT-PCR product), FGFR2 (452 bp RT-St. Louis, MO, USA) and 0.01% H2O2 in TBS. The
reaction was stopped with water, and sections were dehy- PCR product), FGFR3 (431 bp RT-PCR product), and
FGFR4 (434 bp RT-PCR product) were present in E14,drated, cleared, and mounted.
E17, and E21 rat metanephroi (Fig. 2). No RT-PCR
Immunohistochemistry products were detected in the H2O or non-RT controls,
with the exception of FGFR3, in which small amountsImmunohistochemistry was performed as previously
described [35]. Briefly, sections were dewaxed, rehy- of contaminating genomic DNA (approximately 950 bp
product) were amplified in the non-RT control sample ofdrated, and digested in 0.02% trypsin solution (Com-
monwealth Serum Laboratories, Melbourne, Australia) E21 metanephroi. The results are summarized in Table 2.
RT-PCR for FGFR1 through FGFR3 IIIb and IIIcfor 30 minutes at room temperature. Sections were then
treated with 6% H2O2 for 10 minutes to remove endoge- variants. RT-PCR indicated that mRNAs for FGFR1
IIIb (350 bp RT-PCR product), FGFR1 IIIc (348 bp RT-nous peroxidase activity. After blocking for one hour,
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Fig. 1. Southern analysis of RT-PCR products for fibroblast growth factors (FGFs) generated from rat metanephric mRNA from embryonic day
14 (E14), E17, and E21. For each age, the non-RT controls are labeled with “2”. The water control is labeled H2O. RT-PCR products for FGF1
through FGF5 and FGF7 through FGF10 are present in metanephroi at all ages examined. FGF6 was expressed in the positive control adult
skeletal muscle (SM) but not in metanephroi at any age examined.
Table 1. Summary of RT-PCR detection of fibroblast growth factor from E14, E17, and E21 rat embryos (Fig. 3). In contrast,
(FGF) expression in rat metanephroi
FGFR3 IIIb mRNA (351 bp RT-PCR product) was not
FGF mRNA E14 E17 E21 expressed in metanephroi until E16. No RT-PCR prod-
FGF1 1 1 1 ucts were detected in the H2O or non-RT controls of
FGF2 1 1 1 any sample. The results are summarized in Table 3.
FGF3 1 1 1
FGF4 1 1 1
Localization of FGF1 mRNAFGF5 1 1 1
FGF6 2 2 2 Fibroblast growth factor 1 mRNA was detected inFGF7 1 1 1
several regions of the developing rat metanephros (Fig.FGF8 1 1 1
FGF9 1 1 1 4A). FGF1 mRNA was detected throughout the ureteric
FGF10 1 1 1 epithelium from the developing papilla to the ureteric
Symbols are: 1, expressed; 2, not expressed. bud tips in the nephrogenic zone (Fig. 4A). Nephrogenic
zone mesenchyme and early nephron elements, including
condensates, comma- and S-shaped bodies, also con-
tained mRNA for FGF1. Expression of FGF1 mRNAPCR product), FGFR2 IIIb (360 bp RT-PCR product),
appeared to decrease with glomerular maturation, withFGFR2 IIIc (318 bp RT-PCR product), and FGFR3 IIIc
(331 bp RT-PCR product) were present in metanephroi a strong signal detected in early capillary loop stage
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Fig. 2. Southern analysis of RT-PCR products for fibroblast growth
factor receptor (FGFR) transmembrane (tm) domain generated from
E14, E17, and E21 rat metanephric mRNA. For each age, the non-RT
controls are labeled with “2” and the water control is labeled H2O.
RT-PCR products for FGFR1, FGFR2, FGFR3, and FGFR4 are present
in metanephroi at all ages examined.
Table 2. Summary of RT-PCR detection of fibroblast growth factor Fig. 3. Southern analysis of RT-PCR products for FGFR1 through
receptor (FGFR) transmembrane (tm) domain expression in FGFR3 IIIb and IIIc variants generated from rat metanephric mRNA
rat metanephroi from E14 through E17 and E21. For each age, the non-RT controls are
labeled with “2” and the water control is labeled H2O. RT-PCR prod-FGFR (tm) E14 E17 E21 ucts for FGFR1 IIIb and IIIc, FGFR2 IIIb and IIIc, and FGFR3 IIIc
are present in metanephroi from E14-E21. RT-PCR products forFGFR1 1 1 1
FGFR3 IIIb are not present in E14 or E15 metanephroi but are presentFGFR2 1 1 1
from E16 through E21.FGFR3 1 1 1
FGFR4 1 1 1
Symbols are: 1, expressed; 2, not expressed.
signal was detected in the corresponding section hybrid-
ized with sense cRNA probe (Fig. 4B).
glomeruli, but less expression in maturing stage glomer- To determine whether the strong signal observed in
uli located at the corticomedullary boundary (Fig. 4A). the nephrogenic zone was due to edge artifact, some E20
All parts of S-shaped bodies expressed FGF1 mRNA. metanephroi were sliced in half prior to embedding in
This pattern altered with tubular development, with only paraffin. Sections were then hybridized under the same
background levels of signal detectable in developing conditions as those described earlier in this article. In
proximal tubules and in the thin undifferentiated epithe- these sections, no signal was detected in the interstitium
lium of the immature loop of Henle, but with an intense along the cut edge of the metanephros (data not shown),
signal observed in developing distal straight and convo- and the pattern of cRNA hybridization in nephron struc-
luted tubules (Fig. 4A). No FGF1 mRNA was detected tures was identical to that described earlier in this article
in complete sections. This indicates that the signal de-in the developing interstitium or in endothelium. No
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Table 3. Summary of RT-PCR detection of fibroblast growth factor Fibroblast growth factor receptor 1
receptor (FGFR) variant expression in rat metanephroi
Immunostaining for FGFR1 was localized in many
FGFR variant E14 E15 E16 E17 E21 structures of the developing E20 metanephros. Immuno-
FGFR1(IIIb) 1 nd nd 1 1 reactivity for FGFR1 was seen in ureteric epithelium
FGFR1(IIIc) 1 nd nd 1 1
of the developing cortex and medulla (Fig. 5I). In theFGFR2(IIIb) 1 nd nd 1 1
FGFR2(IIIc) 1 nd nd 1 1 nephrogenic zone, the nephrogenic mesenchyme was im-
FGFR3(IIIb) 2 2 1 1 1 munoreactive for FGFR1 (Fig. 6A). Significantly, immu-
FGFR3(IIIc) 1 nd nd 1 1
nostaining for FGFR1 was localized in condensing mes-
Symbols are: 1, expressed; 2, not expressed; nd, not determined. enchymal cells at the tips of the ureteric branches (Fig.
6A), indicating that these cells have the capacity to re-
spond to FGFs. This localization was maintained in de-
veloping nephron elements, where comma- and S-shapedtected in the developing nephrogenic zone and cortex
bodies were immunoreactive for FGFR1 (Fig. 6B).was not an edge artifact.
In maturing nephrons, FGFR1 was localized in capil-
Immunohistochemistry lary loop and maturing stage glomeruli (Fig. 6C) and
appeared to be in podocytes, mesangial cells, and glo-Immunohistochemistry was performed on E15 and
merular endothelium. Developing nephron tubules alsoE20 rat metanephroi. A distinct pattern of immunostain-
demonstrated specific immunostaining for FGFR1, withing was detected for each FGFR. In E15 metanephroi,
immunoreactivity localized in proximal and distal convo-FGFR1 was localized to mesenchymal condensates and
luted tubules (Fig. 6C); some cross-sections throughureteric epithelium, with weak localization in the meta-
proximal convoluted tubules were only weakly stained.nephric mesenchyme (Fig. 5A). FGFR2 was localized to
Both the descending and ascending limbs of the primitivethe ureteric epithelium, with very little staining in the
loop of Henle and the immature loop of Henle (Fig. 6D)metanephric and condensing mesenchyme (Fig. 5B). The
were immunostained for FGFR1. Immunoreactivity fordistribution of FGFR3 was similar to FGFR1, with local-
FGFR1 was also detected in capillary endothelium, butization in ureteric epithelium and mesenchymal conden-
not in the developing interstitium (Fig. 6D). FGFR1 wassates, but not in the surrounding metanephric mesen-
also localized in the endothelium of developing bloodchyme (Fig. 5C). Localization of FGFR4 was similar to
vessels and in the tunica media of arteries. The localiza-FGFR2, with immunoreactivity exclusively in the ure-
tion of FGFR1 in rat metanephric structures is summa-teric epithelium at E15 (Fig. 5D). No specific immuno-
rized in Table 4.staining was observed in sections incubated with diluent
or with rabbit serum (data not shown). Preabsorption
Fibroblast growth factor receptor 2of FGFR antibodies with immunizing peptides abolished
Immunoreactivity for FGFR2 in the E20 metanephrosthe immunostaining pattern observed for each antibody
was more restricted than that of FGFR1. The ureteric(Fig. 5E for FGFR1, Fig. 5F for FGFR2, Fig. 5G for
epithelium of the developing cortex and medulla wasFGFR3, and Fig. 5H for FGFR4).
immunostained for FGFR2 (Fig. 5J), as was the caseThe overall differences in localization of each receptor
for FGFR1. However, in the nephrogenic zone, FGFR2at E20 can easily be observed in low-power photomicro-
immunoreactivity was not detected in nephrogenic mes-graphs (Fig. 5 I–L). In brief, FGFR1 immunoreactivity
was detected in several structures throughout the meta- enchyme, condensates, comma- or S-shaped bodies (Fig.
6 E, F). Weak immunostaining was detected in the lowernephros, including the ureteric epithelium and the neph-
rogenic zone (Fig. 5I). FGFR2 immunoreactivity was limbs of late S-shaped bodies (glomerular anlage), and
this localization was maintained in developing glomerulidetected primarily in proximal convoluted tubules and
the ureteric epithelium (Fig. 5J). FGFR3 was detected with immunostaining for FGFR2 observed in capillary
loop and maturing-stage glomeruli (Fig. 6G). In matur-in the nephrogenic zone and developing cortex but was
absent from the ureteric epithelium of the developing ing-stage glomeruli, localization appeared to be in podo-
cytes and mesangial cells but not in endothelium.medulla, where nephron tubules were immunoreactive
(Fig. 5K). FGFR4 immunoreactivity was present in ure- In developing nephron tubules, intense immunostain-
ing was observed in maturing proximal tubules (Fig. 6G),teric epithelium, but was primarily localized in maturing
nephron epithelia (Fig. 5L). No specific immunostaining with weaker staining in distal tubules. In the developing
loop of Henle, immunostaining for FGFR2 was localizedwas observed in sections incubated with diluent, rabbit
serum (data not shown) or with preabsorbed FGFR anti- throughout the primitive loop. With further develop-
ment, strong staining was detected in the thin undifferen-bodies (Fig. 5M for FGFR1, Fig. 5N for FGFR2, Fig.
5O for FGFR3, and Fig. 5P for FGFR4). A detailed tiated epithelium of the immature loop of Henle (Fig.
6H), with weaker staining in the ascending distal limb.description of the localization of each FGFR follows.
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Fig. 4. Nonradioactive in situ hybridization of E20 rat metanephroi using biotin-UTP–labeled FGF1 cRNA probes. Photomicrographs were
obtained using a differential interference contrast microscope (sections not counterstained). (A) Intense signal for FGF1 mRNA is localized in
the developing nephrogenic zone (n). Strong signal is detected in ureteric epithelium (u) and S-shaped bodies (s), whereas only background levels
of signal are seen in maturing glomeruli (g) and proximal convoluted tubules (pc). FGF1 mRNA is also detected in the medulla, in the ureteric
epithelium (u) and in distal tubules (dt) of the immature loop of Henle. The thin undifferentiated epithlium (th) of the immature loop of Henle
and the developing interstitium (im) did not contain FGF1 mRNA. (B) Adjacent section of metanephros hybridized with sense FGF1 cRNA
probe (bar 5 100 mm).
No immunostaining was observed in the interstitium genic mesenchyme was immunoreactive for FGFR3 (Fig.
(Fig. 6H), capillaries, or the endothelium of developing 6I). Immunostaining for FGFR3 was also localized in
blood vessels, although weak immunostaining was ob- condensing mesenchyme (Fig. 6I), again suggesting these
served in the tunica media of developing arteries. The cells have the capacity to respond to a variety of FGFs.
localization of FGFR2 in rat metanephric structures is In developing nephrons, FGFR3 immunostaining was
summarized in Table 4. localized in vesicles, comma-shaped bodies, and S-shaped
bodies (Fig. 6J). More intense immunoreactivity was ob-
Fibroblast growth factor receptor 3 served in the middle limb (loop of Henle and distal
tubule anlagen) of S-shaped bodies (Fig. 6J) and wasIn the E20 metanephros, FGFR3 was also localized
maintained in these epithelia in more mature nephrons.in the ureteric epithelium. However, unlike immuno-
Weak immunostaining was also localized in capillarystaining for FGFR1 and FGFR2, this staining was re-
loop and maturing-stage glomeruli (Fig. 6K). In maturing-stricted to ureteric epithelial cells in the nephrogenic
stage glomeruli, immunoreactivity appeared to be in po-zone, where branching occurs, and was not detected in
docytes and endothelial cells but not in mesangial cells.more mature ureteric epithelium of the medulla, where
Immunostaining for FGFR3 changed with the devel-widening of the developing papilla and collecting ducts
occurs (Fig. 5K). In the nephrogenic zone, the nephro- opment of the tubule anlagen of S-shaped bodies. Intense
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Fig. 5. Low-power micrographs of FGFR1, FGFR2, FGFR3, and FGFR4 protein localization in E15 (A–H ) and E20 (I–P ) rat metanephroi by
immunohistochemistry. (A) FGFR1 immunoreactivity is localized to the ureteric epithelium (u) and condensing mesenchyme (mc). (B) FGFR2
immunostaining is detected in ureteric epithelium (u). (C) Immunoreactivity for FGFR3 is seen in the condensing mesenchyme (mc) and in ureteric
epithelium (u). (D) FGFR4 immunoreactivity is present in ureteric epithelium (u). No immunoreactivity is seen in the preabsorption controls of
E15 metanephroi for FGFR1 (D), FGFR2 (F), FGFR3 (G), or FGFR4 (H). (I) Immunostaining of FGFR1 in an E20 metanephros; in the
developing cortex, the nephrogenic zone (n), proximal convoluted tubules (pc) and distal convoluted tubules (dc) are immunoreactive. All
tubules in the developing medulla are immunoreactive for FGFR1, including ureteric epithelium (u) and distal straight tubules (dt). (J) FGFR2
immunoreactivity is localized to developing proximal convoluted tubules (pc) and ureteric epithelium (u). (K) Immunostaining of FGFR3 is present
in the nephrogenic zone (n) of the cortex and in distal convoluted (dc) and distal straight (dt) epithelia. In the medulla, the ureteric epithelium
is not immunoreactive for FGFR3. (L) Immunoreactivity for FGFR4 is localized to developing proximal (pc) and distal (dc) convoluted tubules
in the cortex and to ureteric epithelium (u) and distal straight tubules (dt) in the medulla. No immunoreactivity is seen in the preabsorption
controls of E20 metanephroi for FGFR1 (M), FGFR2 (N), FGFR3 (O), or FGFR4 (P). Bar in (A) 5 100 mm (for A–H). Bar in (I) 5 200 mm
(for I–L). Bar in (M) 5 200 mm (for M–P).
Cancilla et al: FGFs and FGFRs in developing kidney2034
Fig. 6. High-power photomicrographs of FGFR1, FGFR2, FGFR3, and FGFR4 protein localization in E20 rat metanephroi by immunohistochemis-
try. (A) Immunoreactivity for FGFR1 is seen in ureteric epithelium (u) and mesenchymal condensate (mc). (B) Immunolocalization of FGFR1 is
detected in S-shaped bodies (s), including the developing podocytes (arrowheads). (C) FGFR1 immunostaining is present in proximal (pc) and
distal (dc) convoluted tubules and in all glomerular cells (podocytes are marked by arrowheads). (D) FGFR1 immunoreactivity is localized in the
thin undifferentiated (th) and distal tubule (dt) epithelia of the immature loop of Henle. Staining is also present in the ureteric epithelium (u) of
the medulla, but not in the interstitium (im). (E) Immunoreactivity for FGFR2 is seen in ureteric epithelium (u), but not in mesenchymal condensates
(mc). (F ) Faint staining is seen for FGFR2 in S-shaped bodies (s; podocytes are marked by arrowheads). (G) FGFR2 immunoreactivity is present
in distal convoluted tubules (dc) and intense staining is seen in proximal convoluted tubules (pc). FGFR2 immunostaining in glomeruli is present
in podocytes (arrowheads) and mesangium. (H ) Immunolocalization for FGFR2 is detected in thin undifferentiated (th) and distal tubule (dt)
epithelia of the immature loop of Henle and in the ureteric epithelium (u) of the medulla, but not in the interstitium (im). (I ) In the nephrogenic
zone, FGFR3 immunostaining is seen in ureteric epithelium (u) and mesenchymal condensates (mc). (J ) S-shaped bodies (s) are immunoreactive
for FGFR3 (podocytes are marked by arrowheads). (K) FGFR3 immunoreactivity is present in distal convoluted tubules (dc) but no staining is
seen in proximal convoluted tubules (pc). In glomeruli, immunostaining for FGFR3 is present in podocytes (arrowheads) and endothelium. (L)
FGFR3 immunostaining is seen in distal tubule epithelium (dt), and weak staining is present in thin undifferentiated epithelium (th) of the immature
loop of Henle. Immunoreactivity for FGFR3 is also present in the medullary interstitium (im), but is not detected in the medullary ureteric
epithelium (u). (M) Weak immunostaining for FGFR4 is seen in ureteric epithelium (u), but no staining is present in mesenchymal condensates
(mc). (N ) Weak immunostaining for FGFR4 is detected in S-shaped bodies (s) but not in the developing podocyte layer (arrowheads). (O) FGFR4
immunoreactivity is present in distal (dc) and proximal (pc) convoluted tubules. No immunoreactivity for FGFR4 is detected in glomeruli (podocytes
are marked by arrowheads). (P) FGFR4 immunostaining is present in distal tubule epithelium (dt), with weak staining in ureteric epithelium (u).
No FGFR4 immunoreactivity is detected in the thin undifferentiated epithelium (th) of the immature loop of Henle or in the medullary interstitium
(im). Bar in (A) 5 20 mm (for A–C, E–G, I–K, and M–O). Bar in (D) 5 50 mm (for D, H, L, P).
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Table 4. Summary of immunolocalization patterns for FGFR1, FGFR2, FGFR3, and FGFR4 in E20 rat metanephroi
Metanephric structure FGFR1 FGFR2 FGFR3 FGFR4
Mesenchymal condensate 1 2 1 2
Comma-shaped body 1 6 1 6
S-shaped body 1 6 1 6
Capillary loop stage glomerulus 1 1 1 2
Maturing stage glomerulus 1 1 1 2
Proximal convoluted tubule 1 1 2 1
Distal convoluted tubule 1 1 1 1
Primitive loop of Henle 1 1 1 6
Proximal straight tubule 1 1 1 1
Thin undifferentiated epithelium 1 1 6 2
Distal tubule 1 1 1 1
Metanephric mesenchyme 1 2 1 2
Medullary interstitium 2 2 1 2
Ureteric epithelium: cortex (c), medulla (m) c 1, m 1 c 1, m 1 c 1, m 2 c 6, m 6
Capillary endothelium and blood vessels 1 2 6 2
Symbols are: 1, immunoreactive; 6, weak immunostaining; 2, no immunostaining.
FGFR3 immunoreactivity was localized to developing veloping blood vessels. The localization of FGFR4 in rat
distal tubules (Fig. 6K) but was not detected in proximal metanephric structures is summarized in Table 4.
convoluted tubules. Immunostaining for FGFR3 was lo-
calized throughout the primitive loop of Henle; this local-
DISCUSSIONization was maintained in the immature loop of Henle,
This study has determined by RT-PCR that mRNAswhere immunoreactivity was detected in the thin undif-
for FGF1, FGF2, FGF3, FGF4, FGF5, FGF7, FGF8,ferentiated epithelium and distal epithelium (Fig. 6L).
FGF9, and FGF10 are expressed early (from at leastWeak immunostaining for FGFR3 was observed in the
E14) in rat metanephric development and continue tointerstitium (Fig. 6L), capillaries, the endothelium of
be expressed throughout metanephrogenesis. This largedeveloping blood vessels, and the tunica media of arter-
array of FGFs may interact with all seven functionalies. The localization of FGFR3 in rat metanephric struc-
FGFR variants throughout gestation, except FGFR3-tures is summarized in Table 4.
IIIb, which is not expressed in rat metanephroi until E16.
Fibroblast growth factor receptor 4 FGF6 is not expressed in developing rat metanephroi.
Previous studies have examined the expression ofImmunoreactivity for FGFR4 was primarily detected
FGF1, FGF2, FGF7, and FGF8 in metanephroi. FGF1in maturing nephron structures of the E20 metanephros
is expressed in human fetal kidneys [10], and FGF2(Fig. 5L). Weak immunostaining for FGFR4 was de-
mRNA is present in human fetal kidneys and was local-tected throughout the ureteric epithelium. No immuno-
ized to tubular epithelia, mesangial cells, and surroundingreactivity was detected in the nephrogenic mesenchyme
mesenchyme [11]. FGF7 mRNA has been localized toor in mesenchymal condensates (Fig. 6M). Weak immu-
the renal hilus of neonatal rat kidneys [12], and FGF8nostaining was detected in comma-shaped bodies and in
mRNA has been localized to nephron elements in E14.5the upper and middle limbs of S-shaped bodies (Fig.
and E15.5 mice [13, 14]. We have determined that in6N). However, no staining was detected in the lower
addition to mRNAs for FGF1, FGF2, FGF7, and FGF8,limb of S-shaped bodies or in developing or maturing
expression of FGF3, FGF4, FGF5, FGF9, and FGF10glomeruli (Fig. 6 N, O).
mRNAs were also detected in metanephroi, and that allThe weak immunostaining observed in the tubule an-
nine of these FGFs (FGF1 through FGF5 and FGF7lagen of the S-shaped bodies altered with tubule devel-
through FGF10) are expressed from at least E14 andopment. In maturing nephrons, FGFR4 was immuno-
throughout metanephrogenesis. We have also determinedlocalized to proximal convoluted tubules with some
that FGF6 is not expressed by rat metanephroi at anycross-sections only weakly stained, and intense staining
stage of gestation.was detected in distal tubules (Fig. 6O). FGFR4 immu-
Several FGF knockout mice have been generated, withnoreactivity was detected in the primitive loop of Henle.
varying severity of phenotypes. Knockout mice for FGF2In the immature loop of Henle, FGFR4 was not detected
[36, 37], FGF3 [38], FGF5 [39], and FGF6 [40] do notin the thin undifferentiated epithelium but was detected
have any obvious kidney defects, suggesting that thesein the distal ascending epithelium (Fig. 6P). No immuno-
growth factors are not essential for kidney formation, orreactivity for FGFR4 was detected in the interstitium
(Fig. 6P), capillaries, or the endothelium or walls of de- that other factors can compensate for their loss. FGF4
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knockout mice are peri-implantation lethal; therefore, cultured rat metanephric mesenchyme in that it induces
mesenchymal condensation [9]. In vivo, FGF2 mRNAmetanephrogenesis cannot be examined in these mice
[41]. Interestingly, abrogation of FGFR2 IIIb signaling [11] and protein [15] were localized in the metanephric
mesenchyme. The cells of this region either remain pro-in dominant-negative receptor mutant mice results in
severe kidney defects [42]. Of the well-documented liferative or differentiate into a condensate. FGFs may
be involved in both of these functions by maintainingFGFs, FGF1, FGF3, FGF7, and FGF10 are known to
bind and signal through FGFR2 IIIb [19, 20]. As men- mesenchymal proliferation and by inducing mesenchy-
mal condensation.tioned, FGF3 knockout mice show no obvious kidney
phenotype; however, FGF7 knockout mice have 30% Several studies have examined the expression of
FGFRs in metanephroi. Northern analysis of 17- to 18-fewer nephrons than their wild-type littermates [43]. The
mild phenotype seen in FGF7 knockout mice suggests week-old human fetal tissues showed that FGFR1,
FGFR2, FGFR3, and FGFR4 are expressed in devel-that other FGFs, perhaps FGF1 or FGF10 or both, have
a pivotal role in kidney development. A role for FGF10 oping human kidneys [21]. Three splice variants of
FGFR1 were detected by RT-PCR in rat metanephroiin branching morphogenesis of the lung has been demon-
strated in FGF10 knockout animals [44]; the kidneys of at E14, E17, and E20 [22], demonstrating that FGFR1
is expressed throughout metanephrogenesis. FGFR1,these mice were not described.
Fibroblast growth factor 1 can interact with the seven FGFR3, and FGFR4 were detected in E21 rat kidneys
by RT-PCR [23]. These RT-PCR data are in agreementdifferent FGFR variants [19], all of which were expressed
in metanephroi. The localization of FGF1 mRNA did not with Kim et al [22] and have extended the findings of
Kee et al [23] by demonstrating expression of all fouroverlap entirely with the localization of FGFR1 through
FGFR4 protein observed in metanephroi. No expression FGFRs and all seven FGFR variants throughout rat met-
anephrogenesis. The absence of FGFR3 IIIb at E14 andof FGF1 mRNA was detected in proximal tubules, thin
undifferentiated limbs of the immature loop of Henle, E15 suggests that this FGFR variant is not expressed
until more mature structures have developed in the E16or the medullary interstitium. However, FGFR proteins
were localized to these structures, indicating that other rat metanephros.
Several studies have examined the localization ofFGFs interact with these receptors.
We have previously shown that FGF1 and FGF2 pro- FGFR mRNAs in developing embryos by radioactive in
situ hybridization [11, 24–26, 28, 29]. However, the majortein are present in the epithelium of developing nephron
elements, from the vesicle stage to S-shaped bodies, and focus of these studies was not the developing kidney,
and only brief descriptions of localization in metanephroiin the developing glomerular mesangium of metanephroi,
but not in mesenchymal condensates, endothelial cells, were provided. Close examination of the photomicro-
graphs provided in these reports suggests that the FGFRor the thin undifferentiated epithelium of the immature
loop of Henle [15]. In this study, FGF1 mRNA had a protein localization results of this study are generally in
agreement with these previous studies on FGFR mRNAsimilar distribution to FGF1 protein except the mRNA
was also detected in mesenchymal condensates and ma- localization.
Several studies have localized FGFR1 mRNA by inturing stage glomeruli. This difference may be due to
differences in sensitivity of detection between immuno- situ hybridization in developing rat and mouse kidneys
[24–26]. Analysis of the photomicrographs provided inhistochemistry and in situ hybridization. Alternatively,
although the mRNA is present, there may be a delay in these studies shows that FGFR1 is expressed in collecting
ducts, metanephric and condensing mesenchyme, vesi-protein synthesis until the condensate has converted into
epithelium. A similar delay in protein synthesis has been cles, comma- and S-shaped bodies, developing glomeruli,
and nephron tubules. The protein localization data ofobserved for the HSPG syndecan. Although syndecan
mRNA is present throughout the mesenchyme of the this study are in good agreement with these previous
studies. In human metanephroi, FGFR1 protein andearly metanephros, syndecan protein is only present in
induced mesenchyme around the ureteric bud [45]. In mRNA have been localized in renal tubules (including
collecting ducts) and early nephron structures (comma-glomeruli, FGF1 mRNA levels appeared to decrease
with maturation, whereas intense immunoreactivity for and S-shaped bodies); mRNA and protein were also
detected in the surrounding stroma [11]. The antibodyFGF1 protein was localized in the mesangium through-
out glomerular development [15]. FGFs are heparin- used by Gonzalez et al was made against the carboxy-
terminus of human FGFR1, similar to the commercialbinding proteins and may be synthesized early in glomer-
ular formation and bind to the mesangial ECM, and antibody used in this study [11]. Although Gonzalez et
al only provided a photomicrograph of a single glomeru-therefore, FGF protein could be detected in the mesan-
gium of maturing stage glomeruli. lus, the description of FGFR1 protein localization in
human metanephroi matches that observed in rat meta-Perantoni, Dove, and Karavanova showed that FGF2
could imitate the early events of an inductor tissue in nephroi [11]. Targeted mutations of FGFR1 are embry-
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onic lethal prior to kidney formation [46, 47]; therefore, Fibroblast growth factor receptor 3 mutant mice have
skeletal dysplasias with elongation of the long bones [50,the role of this receptor in metanephrogenesis cannot
be determined in these mice. 51], whereas FGFR4 mutants are phenotypically normal
[49]. Mice that are mutant for both FGFR3 and FGFR4The pattern of FGFR2 mRNA expression has been
described in mouse embryos [25, 26]. FGFR2 was ex- display phenotypes, which are not present in either
FGFR3 or FGFR4 single mutants [49]; these mice displaypressed in collecting ducts and some nephron tubules.
However, the resolution of the radioactive in situ hybrid- severe dwarfism and lung abnormalities. The broad dis-
tribution of FGFRs in metanephroi suggests that co-ization does not allow an accurate assessment of the exact
tubule types expressing FGFR2. In addition to localiza- operativity between FGF ligands and the receptors is
important for the formation and maturation of meta-tion in ureteric epithelium, this study identified these
FGFR2-expressing nephron tubules as proximal and dis- nephroi.
Capillary loop stage glomeruli were immunoreactivetal convoluted tubules. Targeted disruption of FGFR2
IIIc is peri-implantation lethal [48]; therefore, the role of for FGFR1, FGFR2, and FGFR3. This localization ap-
peared to change with glomerular maturation. Althoughthis receptor cannot be assessed in these mice. However,
transgenic mice expressing a soluble dominant-negative localization of reaction products from immunohisto-
chemistry by light microscopy is not always accurate,FGFR2 IIIb have severe kidney defects [42]. The kidneys
either failed to develop or formed a small disorganized differences in localization of these receptors in the three
cell types of maturing stage glomeruli were evident. Ma-organ with small glomeruli and enlarged vacuolated tu-
bules. Markers of early nephron development were not turing podocytes (glomerular epithelial cells) were im-
munoreactive for FGFR1, FGFR2, and FGFR3, whereasexpressed in severely affected mutant mice; the authors
suggest that the dominant-negative receptor disrupted maturing mesangial cells were immunoreactive for FGFR1
and FGFR2 only, and maturing glomerular endothelialthe induction of ureteric bud outgrowth and mesenchy-
mal-epithelial conversion [42]. cells were immunoreactive for FGFR1 and FGFR3 only.
These emerging differences in FGFR expression needIn situ hybridization studies on the expression pattern
of FGFR4 in murine development has shown that it is to be confirmed at the electron microscope level before
firm conclusions can be drawn. However, these resultsexpressed in a number of tissues including metanephroi
[28, 29]. Within metanephroi, FGFR4 expression was suggest that there may be differences in ligand respon-
siveness between different glomerular cell populations,found in collecting tubules at E14.5. Closer examination
of the photomicrograph provided by Stark, McMahon, and these differences may be important for glomerular
maturation. Although all glomerular cells were immuno-and McMahon shows that FGFR4 mRNA is expressed
in ureteric epithelium in the cortex but not medulla and reactive for FGFR1, different cell types may express sev-
eral functional variants, thus further refining the ligandthat developing nephron tubules also express FGFR4
mRNA, although developing glomeruli appear negative interactions in these cells. We have recently described
the expression pattern of FGFR IIIb and IIIc isoforms[28]. This expression pattern is similar to the protein
localization described in this study, where nephron tu- in adult rat glomeruli [32]. We found that the IIIc iso-
forms of FGFR1, FGFR2, and FGFR3, as well as FGFR4,bules were intensely immunoreactive for FGFR4, but
no immunostaining in glomeruli and only weak immuno- were expressed in normal glomeruli, whereas the IIIb
isoforms of FGFR1, FGFR2, and FGFR3 were not.staining were found in ureteric epithelium. However,
FGFR4 knockout mice are developmentally normal and Ureteric epithelium expressed all four FGFRs. A nota-
ble difference in localization was observed for FGFR3,do not have any overt organ defects [49].
Metanephric mesenchyme and mesenchymal conden- which was limited to cortical ureteric epithelium. This
expression pattern suggests that FGFR3 may be moresates were immunoreactive for FGFR1 and FGFR3. The
major ligands of these receptors are FGF1, FGF2, FGF4, important for the mitogenic response of growing ureteric
tips or for ureteric bud branching. No obvious kidneyand FGF9 [19]. All four ligands are expressed by meta-
nephroi, but whether FGF4 or FGF9 are present in mes- defects have been described in FGFR3 knockout mice
[50, 51], suggesting that other FGFRs may compensateenchymal condensates has not yet been determined.
FGFR3 IIIb is not expressed until E16, suggesting that for the loss of FGFR3 or that cooperation between
FGFR3 and another FGFR may be required.the mesenchymal condensate localization of FGFR3 pro-
tein is due to the IIIc variant. Cytoplasmic immunostain- Appropriate activation of FGFRs by FGFs requires
HSPGs [16, 17]. During metanephric development, sul-ing for FGF1 and FGF2 was observed in the epithelial
vesicles that form from the mesenchymal condensates fated proteoglycans are initially produced at the ureteric
bud tips and are subsequently found in basement mem-[15]. Weak immunoreactivity for FGFR2 and FGFR4
also emerged following conversion of mesenchyme to branes throughout the metanephros [18]. In mouse meta-
nephric organ culture, inhibition of sulfated proteogly-epithelium, suggesting these receptors play a role in
nephron maturation. can synthesis impairs ureteric bud branching [52–54].
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